Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 516 participants.

Also called NCT06037889

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 516 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06037889
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06037889. Randomized; single masking; primary purpose treatment. Start 2023-11-09 (actual); primary completion 2026-02-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
Acronym
BRANT
Condition
Branch Atheromatous Disease
Intervention (Drug)
Tirofiban
Intervention (Drug)
Aspirin tablet
Intervention (Drug)
Clopidogrel tablet
Lead sponsor
Peking Union Medical College Hospital (class: other)
Collaborator
Pharmaron (Chengdu) Clinical Services Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct06037889
Content hash
d5949b2db7f07505780f1c13b6716cdf73cac7b66096b1c7b97e7ccd9582e4e7